Clinical Application and Selection Considerations of HLA-B27 Detection Kits in the Diagnosis of Spondyloarthritis

Clinical Significance and Target Population of HLA-B27 Testing

HLA-B27 is the abbreviation for human leukocyte antigen B27 subtype. Its positivity is strongly associated with spondyloarthritis (SpA), including ankylosing spondylitis, reactive arthritis, and psoriatic arthritis, but it is not a diagnostic gold standard. In clinical practice, HLA-B27 test kits are mainly applied in the following scenarios: assisting in the etiological classification of patients with chronic low back pain, evaluating the potential rheumatologic background in patients with uveitis, and preliminary screening for familial aggregation tendency. It should be noted that positive results require comprehensive interpretation in conjunction with imaging and clinical symptoms, and negative results cannot completely exclude SpA.

Comparison of Mainstream Detection Technologies and Basis for Kit Selection

Currently available HLA-B27 test kits on the market are mainly based on flow cytometry or polymerase chain reaction (PCR). The flow cytometry method directly detects cell surface HLA-B27 antigen using fluorescently labeled monoclonal antibodies. It is rapid and suitable for high-throughput screening, but may be interfered with by cross-reactivity (e.g., with HLA-B7, B42), requiring optimization of antibody combinations. PCR kits detect HLA-B27 alleles (e.g., B*27:01-27:06) at the genetic level, offering higher specificity and supplementary value for weakly positive or difficult samples, but they are more time-consuming and require specialized equipment. When selecting kits, laboratories should consider their own testing volume, turnaround time requirements, and the convenience of subsequent result verification. It is generally recommended to equip both a screening method and a confirmatory method.

Common Misconceptions and Precautions in Result Interpretation

Interpretation of HLA-B27 test kit results requires vigilance against several issues: First, certain HLA-B27 subtypes (e.g., B*27:07 or B*27:09) carried by some populations have low association with SpA, and kits that do not distinguish subtypes may produce false-positive associations. Second, in flow cytometry, cell viability and anticoagulant type may affect fluorescence intensity, leading to misinterpretation near the cutoff value. Third, laboratories should regularly participate in external quality assessment and establish their own positive threshold criteria. After receiving a positive report, clinicians should comprehensively evaluate the patient's symptoms, imaging findings, and inflammatory markers to avoid causing unnecessary anxiety in healthy carriers.

Regulatory Compliance and Performance Verification Points for Test Kits

According to national medical device classification, HLA-B27 test kits are typically managed as Class II or Class III medical devices (depending on whether the detection target involves genetic testing). When introducing new batches of test kits, laboratories should complete performance verification according to the manufacturer's instructions, including at minimum accuracy, precision, linear range (if applicable), and consistency comparison with reference methods. In routine testing, it is recommended to include negative and positive quality control materials with each run and record abnormal value trends. Batch numbers and expiration dates should be archived in compliance with regulations to ensure traceability.

In summary, the rational selection and standardized operation of HLA-B27 test kits is an important component of improving the diagnostic efficiency of spondyloarthritis, but technical limitations must be recognized, and comprehensive clinical interpretation should always be the prerequisite.